Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 677 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Morning Group Clear all
Suspended No phase listed Observational

Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA)

NCT04838223
View directory record Official record
Conditions
Dry Eye, Neuropathic Pain
Interventions
Hyperosmolar Response, Proparacaine Challenge Test, Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Optional; only for Contact Lens Wearers, Ocular Pain Assessment Survey (OPAS), Visual Analogue Questionnaire
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
16
States / cities
Azusa, California • Pomona, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03891524
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg, JNJ-70033093 200 mg, Placebo, Enoxaparin 40 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

NCT00464269
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 22, 2026, 10:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

NCT07304024
View directory record Official record
Conditions
Central Auditory Processing Disorder, Hearing Impaired (Partially), Hearing, Hearing Abnormality, Hearing Disability, Hearing Disorder, Hearing Disorders, Hearing Impairment, Sensorineural, Hearing Handicap, Hearing Impaired, Hearing Impairment, Hearing Loss, Central Auditory Disease, Noise Exposure, Noise Induced Hearing Loss, Noise-Induced Hearing Loss, Sound Perception, Myelin Degeneration, Myelinopathy, Myelin Integrity, Remyelination, Hidden Hearing Loss, Cocktail Party Skill, Cocktail Party Syndrome, CAPD, Age Problem
Interventions
Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound, Placebo - Placebo
Combination Product · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 22, 2026, 10:41 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Music Training and Child Development Study

NCT05502939
View directory record Official record
Conditions
Music
Interventions
Music Program, After School Enrichment Program
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
6 Years to 8 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

NCT04223349
View directory record Official record
Conditions
Healthy
Interventions
JNJ-70033093, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 22, 2026, 10:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Circadian Intervention to Improve Cardiometabolic Health

NCT05943626
View directory record Official record
Conditions
Cardiometabolic Syndrome, Type 2 Diabetes, Sleep, Time Restricted Feeding, Lifestyle Factors, Overweight and Obesity, Insulin Sensitivity, Eating Habit, Sleep Hygiene
Interventions
Circadian Intervention
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Impact of Ashwagandha on Perceived Stress, Sleep and Food Cravings in College Students

NCT05430685
View directory record Official record
Conditions
Stress, Sleep, Craving, Well Being
Interventions
Ashwagandha, Placebo
Dietary Supplement · Other
Lead sponsor
University of Colorado, Colorado Springs
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2022 · Synced Oct 22, 2026, 10:41 PM EDT
Active, not recruiting Not applicable Interventional

Efficacy of A Novel RinSe Device to Reduce Oral Bacteria in Intubated IntEnsive CaRe Patients: a Pilot Study

NCT06193512
View directory record Official record
Conditions
Oral Bacterial Infection, Mechanical Ventilation Complication
Interventions
SwishKit + Oral care treatment as usual, Oral care treatment as usual
Device · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep and Cardiovascular Health in Adolescence

NCT03727906
View directory record Official record
Conditions
Insomnia Type; Sleep Disorder
Interventions
No pre-sleep arousal manipulation, pre-sleep arousal down-regulation, pre-sleep arousal up-regulation
Other
Lead sponsor
SRI International
Industry
Eligibility
16 Years to 20 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

NCT02058147
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
118
States / cities
Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 22, 2026, 10:41 PM EDT
Recruiting Not applicable Interventional

Effects of Binaural Beats and Spatialized Music on Behavioural and Psychological Symptoms of Dementia in Assisted Living Facility Residents

NCT07626944
View directory record Official record
Conditions
BPSD, Caregiver Distress, Well-being, Mood
Interventions
Personalized Music Listening (PML), Binaural Beat Music (BBM), Spatialized Music (SM)
Other
Lead sponsor
Maharishi International University
Other
Eligibility
55 Years to 95 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Denver, Colorado • Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 22, 2026, 10:41 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

NCT05593614
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
ATX01 10%, ATX01 15%, Placebo
Drug
Lead sponsor
AlgoTherapeutix
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Clermont, Florida • Miami, Florida • Port Charlotte, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder

NCT00758498
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Atlanta, Georgia • Crestview, Kentucky • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

NCT01754116
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral, GSK1265744 400 mg (200 nm), GSK1265744 400 mg (1 micro m), GSK1265744 400 mg (5 micro m)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Vitamin E on Non-Alcoholic Fatty Liver Disease

NCT02690792
View directory record Official record
Conditions
Healthy, NAFLD (Non-Alcoholic Fatty Liver Disease), NASH (Non-Alcoholic Steatohepatitis)
Interventions
NAFLD/NASH - Placebo, NAFLD/NASH - Vitamin E
Other · Dietary Supplement
Lead sponsor
Jeffrey Browning
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

NCT01156844
View directory record Official record
Conditions
Persistent Asthma
Interventions
Indacaterol, Placebo to Indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
21
States / cities
Anniston, Alabama • Cypress, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Effect of a Supplement on Symptoms of Hormonal Imbalance.

NCT06535698
View directory record Official record
Conditions
Women's Health
Interventions
Perelel Health Hormonal Balance Support
Dietary Supplement
Lead sponsor
Perelel Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects

NCT02223832
View directory record Official record
Conditions
Healthy
Interventions
ACT-128800
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

NCT05469464
View directory record Official record
Conditions
Atopic Dermatitis, Skin Diseases
Interventions
Orismilast modified release tablets, Placebo
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Canoga Park, California • Fountain Valley, California • Inglewood, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Foot Reflexology in Ocular Hypertensive and Glaucoma Patients

NCT04695314
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
Massage, Experimental insert, Sham insert
Device · Procedure
Lead sponsor
Temple University
Other
Eligibility
30 Years to 90 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 22, 2026, 10:41 PM EDT
Terminated Phase 4 Interventional Results available

Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

NCT03296033
View directory record Official record
Conditions
Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity
Interventions
Enoxaparin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 100 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 22, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

NCT03573817
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Revefenacin, Placebo, Formoterol
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 22, 2026, 10:41 PM EDT
Enrolling by invitation Phase 2 Interventional

Bright Light Therapy for Depressed Geriatric Inpatients

NCT07002554
View directory record Official record
Conditions
Unipolar Depression
Interventions
Bright light therapy, dim red light
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 22, 2026, 10:41 PM EDT